References
- Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
- Jensen RM, Lyngberg A, Jensen RH. Burden of cluster headache. Cephalalgia. 2007;27:535–541.
- Ford JH, Nero D, Kim G, et al. Societal burden of cluster headache in the United States: a descriptive economic analysis. J Med Econ. 2018;21:107–111.
- Vikelis M, Rapoport AM. Cluster headache in Greece: an observational clinical and demographic study of 302 patients. J Headache Pain. 2016;17:88.
- Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol. 2018;17:75–83.
- Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev. 2013;7:CD008042.
- Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA. 2009;302:2451–2457.
- Petersen AS, Barloese MC, Lund NL, et al. Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study. Cephalalgia. 2017;37:214–224.
- Robbins MS, Starling AJ, Pringsheim TM, et al. Treatment of cluster headache: the American headache society evidence-based guidelines. Headache. 2016;56:1093–1106.
- Afridi SK, Shields KG, Bhola R, et al. Greater occipital nerve injection in primary headache syndromes–prolonged effects from a single injection. Pain. 2006;122:126–129.
- Leroux E, Valade D, Taifas I, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10:891–897.
- Petersen AS, Barloese MCJ, Snoer A, et al. Verapamil and cluster headache: still a mystery. A narrative review of efficacy, mechanisms and perspectives. Headache. 2019;59:1198–1211.
- May A, Schwedt TJ, Magis D, et al. Cluster headache. Nat Rev Dis Primers. 2018;4:18006.
- D’Andrea G, Bussone G, Di Fiore P, et al. Pathogenesis of chronic cluster headache and bouts: role of tryptamine, arginine metabolism and α1-agonists. Neurol Sci. 2017;38:37–43.
- Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache. 2019;59:20–32.
- Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117:427–434.
- Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338–350.
- Fischera M, Marziniak M, Gralow I, et al. The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia. 2008;28:614–618.
- Lund N, Barloese M, Petersen A, et al. Chronobiology differs between men and women with cluster headache, clinical phenotype does not. Neurology. 2017;88:1069–1106.
- Solomon S, Karfunkel P, Guglielmo KM. Migraine-cluster headache syndrome. Headache. 1985;25:236–239.
- Vollesen AL, Benemei S, Cortese F, et al. Migraine and cluster headache - the common link. J Headache Pain. 2018;19:89.
- Peng KP, Takizawa T, Lee MJ. Cluster headache in Asian populations: similarities, disparities, and a narrative review of the mechanisms of the chronic subtype. Cephalalgia. 2020;40:1104–1112.
- Bahra A, May A, Goadsby PJ. Cluster headache: A prospective clinical study with diagnostic implications. Neurology. 2002;58:354–361.
- Liampas I, Siokas V, Brotis A, et al. Meta-analysis of melatonin levels in cluster headache-review of clinical implications. Acta Neurol Scand. 2020 Jul 17. DOI:10.1111/ane.13317.
- Robbins MS, Robertson CE, Kaplan E, et al. The sphenopalatine ganglion: anatomy, pathophysiology, and therapeutic targeting in headache. Headache. 2016;56:240–258.
- Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalalgia. Lancet Neurol. 2002;1:251–257.
- Hoffmann J, Baca SM, Akerman S. Neurovascular mechanisms of migraine and cluster headache. J Cereb Blood Flow Metab. 2019;39:573–594.
- Edvardsson B. Symptomatic cluster headache: a review of 63 cases. Springerplus. 2014;3:1–8.
- Leone M, Franzini A, Broggi G, et al. Acute hypothalamic stimulation and ongoing cluster headache attacks. Neurology. 2006;67:1844–1845.
- Vyas DB, Ho AL, Dadey DY, et al. Deep brain stimulation for chronic cluster headache: a review. Neuromodulation. 2019;22:388–397.
- De Pue A, Lutin B, Paemeleire K. Chronic cluster headache and the pituitary gland. J Headache Pain. 2016;17:23.
- Vollesen ALH, Snoer A, Beske RP, et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol. 2018;75:1187–1197.
- Snoer A, Vollesen ALH, Beske RP, et al. Calcitonin-gene related peptide and disease activity in cluster headache. Cephalalgia. 2019;39:575–584.
- Csati A, Tajti J, Kuris A, et al. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. Neuroscience. 2012;202:158–168.
- Edvinsson L, Tajti J, Szalárdy L, et al. PACAP and its role in primary headaches. J Headache Pain. 2018;19:21.
- Tuka B, Szabo N, Toth E, et al. Release of PACAP-38 in episodic cluster headache patients - An exploratory study. J Headache Pain. 2016;17:69.
- D’Andrea G, Gucciardi A, Perini F, et al. Pathogenesis of cluster headache: from episodic to chronic form, the role of neurotransmitters and neuromodulators. Headache. 2019;59:1665–1670.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:1000100.
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting 536 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
- Higgins JPT, Thomas J, Chandler J, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, 2019
- Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
- Silberstein SD, Mechtler LL, Kudrow DB, et al. Non-invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache. 2016;56:1317–1332.
- Dirkx THT, Haane DYP, Koehler PJ. Oxygen treatment for cluster headache attacks at different flow rates: a double-blind, randomized, crossover study. J Headache Pain. 2018;19:94.
- Goadsby PJ, de Coo IF, Silver N, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia. 2018;38:959–969.
- Goadsby PJ, Sahai-Srivastava S, Kezirian EJ, et al. Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. Lancet Neurol. 2019;18:1081–1090.
- Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381:132–141.
- Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia. 2020;40:935–948.
- Gaul C, Diener HC, Silver N, et al. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): a randomised controlled study. Cephalalgia. 2016;36:534–546.
- [ cited 2020 Oct 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT02964338.
- [ cited 2020 Oct 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT02945046
- Safety and efficacy of Lysergic Acid Diethylamide (LSD) as treatment for cluster headache: a randomized, double-blind, placebo-controlled Phase II study – full text view - clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03781128
- Randomized, double-blind, multi-center, parallel-group comparison of the efficacy and safety of the C213 (Zolmitriptan microneedle system) to placebo for the acute treatment of cluster headaches – full text view - clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04066023
- GON-injection for a sooner and better treatment of cluster headache: a double-blind randomized controlled trial – full text view – clinicaltrialsregister.eu. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002224-17/NL
- Botulinum toxin type a blockade of the sphenopalatine ganglion in treatment-refractory chronic cluster headache – full text view – clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03944876
- Sandrini G, De Icco R, Tassorelli C, et al. Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. J Headache Pain. 2017;18:38.
- Rapoport AM, McAllister P. The headache pipeline: excitement and uncertainty. Headache. 2020;60:190–199.
- United States Food and Drug Administration. FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks; [ cited 2020 Nov 8]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-episodic-cluster-headache-reduces-frequency-attacks
- European Medicines Agency. Assessment report. Emgality. [ cited 2020 Nov 8]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/emgality-h-c-04648-x-0004-epar-refusal-public-assessment-report_en.pdf